AbbVie receives two FDA designations: stock after-hours at EUR 243.40, plus 3.20 percent
Published on 10/07/2026 at 20:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie announced two U.S. Food and Drug Administration Breakthrough Therapy Designations for telisotuzumab adizutecan, also known as Temab-A or ABBV-400, on October 7, 2026, in a release distributed by PR Newswire. The stock was at EUR 243.40 after-hours at 8:04 p.m. CEST at Lang & Schwarz, up 3.20 percent versus the prior close.
AbbVie stock after-hours
Lang & Schwarz recorded a previous close of EUR 235.85 for AbbVie. The bid was EUR 243.10 and the ask was EUR 243.70 at the October 7, 2026, timestamp. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of AbbVie stock.
Two cancer indications receive FDA designations
The first designation covers Temab-A in combination with bevacizumab for adults with refractory, metastatic colorectal cancer who have received specified prior treatments. The second covers Temab-A as a monotherapy for adults with locally advanced or metastatic EGFR wild-type, c-Met protein-expressing, non-squamous non-small cell lung cancer after platinum-based chemotherapy and anti-PD-(L)1 treatment, according to the company release.
AbbVie said the designations were primarily based on results from the first-in-human M21-404 study. Temab-A remains investigational and has not been approved by global regulatory authorities. The company said the program includes Phase 3 and Phase 2/3 studies across several advanced solid tumors, including colorectal and lung cancers, in the same release.
